We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.34B
1-Year Est. Return
204.53%
This Fund
S&P 500
This Quarter
Est. Return
+11.43%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$970M
AUM Growth
+$46.5M
(+5%)
Cap. Flow
-$12.4M
Cap. Flow
% of AUM
-1.28%
Top 10 Holdings %
Top 10 Hldgs %
72%
Holding
47
New
11
Increased
7
Reduced
11
Closed
10
Top Buys
| 1 |
KYNB
Kyntra Bio
KYNB
|
+$58.8M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$42.9M |
| 3 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
+$34.9M |
| 4 |
BCEL
Atreca, Inc. Class A Common Stock
BCEL
|
+$26.8M |
| 5 |
Cyclerion Therapeutics
CYCN
|
+$11M |
Top Sells
| 1 |
Ascendis Pharma A/S
ASND
|
+$42.5M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$31.3M |
| 3 |
argenx
ARGX
|
+$31M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$24.9M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$21M |
Sector Composition
| 1 | Healthcare | 88.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Kura Oncology
KURA
$999M
| $104M | 10.71% |
5,276,753
| – | – |
|
2
Xencor
XNCR
$1.1B
| $95.6M | 9.86% |
2,336,557
+277,128
| +13% | +$9.1M |
|
|
3
argenx
ARGX
$54B
| $82.3M | 8.48% |
581,165
-243,922
| -30% | -$31M |
|
4
CRISPR Therapeutics
CRSP
$4.97B
| $75.8M | 7.82% |
1,610,250
-268,027
| -14% | -$10.7M |
|
|
KYNB
5
Kyntra Bio
KYNB
$29.5M
| $68.3M | 7.04% |
60,471
+53,736
| +798% | +$58.8M |
|
|
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $62.9M | 6.48% |
614,128
+85,128
| +16% | +$9.19M |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $61.6M | 6.34% |
597,711
-402,289
| -40% | -$31.3M |
|
|
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $52.2M | 5.38% |
3,316,407
| – | – |
|
9
Ironwood Pharmaceuticals
IRWD
$667M
| $51.1M | 5.27% |
4,671,408
-578,811
| -11% | -$6.48M |
|
|
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $44.9M | 4.63% |
+2,266,804
| New | +$42.9M |
|
11
Ultragenyx Pharmaceutical
RARE
$3.1B
| $31.6M | 3.26% |
497,899
| – | – |
|
|
PRVL
12
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $31.6M | 3.25% |
+2,392,556
| New | +$34.9M |
|
|
BCEL
13
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $28M | 2.89% |
+1,486,979
| New | +$26.8M |
|
|
CHMA
14
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $22.7M | 2.34% |
3,043,827
| – | – |
|
|
HARP
15
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $17.5M | 1.81% |
134,842
+1,200
| +0.9% | +$139K |
|
16
Gossamer Bio
GOSS
$72.8M
| $17.1M | 1.76% |
772,096
| – | – |
|
|
ARQL
17
DELISTED
Arqule Inc
ARQL
| $14.3M | 1.48% |
+1,300,000
| New | +$9.05M |
|
|
EIGR
18
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $12M | 1.24% |
37,868
-15,320
| -29% | -$5.3M |
|
19
Arcus Biosciences
RCUS
$3.51B
| $11.8M | 1.21% |
1,488,205
+498,059
| +50% | +$4.99M |
|
|
UBX
20
DELISTED
Unity Biotechnology
UBX
| $9.92M | 1.02% |
104,450
+13,789
| +15% | +$1.17M |
|
|
21
Cyclerion Therapeutics
CYCN
$16.5M
| $8.89M | 0.92% |
+38,810
| New | +$11M |
|
22
Prothena Corp
PRTA
$447M
| $7.64M | 0.79% |
723,300
-3,219
| -0.4% | -$33.1K |
|
|
RUBY
23
DELISTED
Rubius Therapeutics, Inc
RUBY
| $7.29M | 0.75% |
463,152
-183,076
| -28% | -$2.95M |
|
|
SURF
24
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $6.52M | 0.67% |
2,312,688
+49,200
| +2% | +$196K |
|
|
MRSN
25
DELISTED
Mersana Therapeutics
MRSN
| $5.64M | 0.58% |
55,689
-36,311
| -39% | -$4.28M |
|
Similar funds
G
MC
BAM
CC
HFM
NO
ST
MFAM